Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis B vaccination - before a breakthrough?]

P J Grob

    Schweizerische Medizinische Wochenschrift
    |August 4, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Hepatitis B vaccination is being introduced in Switzerland, offering over 90% protection against HBV infection. Vaccines are safe and effective for most individuals, with recommendations for high-risk groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Altered intracellular expression of the chemokines MIP-1alpha, MIP-1beta and IL-8 by peripheral blood CD4+ and CD8+ T cells in mild allergic asthma.

    Allergy·2003
    Same author

    [Hepatitis B virus infection: diagnosis, clinical sequelae, therapy and prevention].

    Praxis·2002
    Same author

    Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.

    Journal of acquired immune deficiency syndromes (1999)·2001
    Same author

    [Hepatitis C virus infection. Overview. SEVHEP (Swiss Experts on Viral Hepatitis)].

    Praxis·2000
    Same author

    Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.

    AIDS (London, England)·1999
    Same author

    Hepatitis B: virus, pathogenesis and treatment.

    Vaccine·1999
    Same journal

    Respiratory function test in the case of temporary phrenic nerve contusion, associated with pneumoperitoneum; About the diagnostic value of laparoscopy.

    Schweizerische medizinische Wochenschrift·2010
    Same journal

    Treatment of pulmonary tuberculosis and pleurisy by means of temporary paralysis of the diaphragm, supported by the pneumoperitoneum.

    Schweizerische medizinische Wochenschrift·2010
    Same journal

    Boeck's disease as a tuberculous syndrome.

    Schweizerische medizinische Wochenschrift·2010
    Same journal

    Enteral primary tubercular complexes

    Schweizerische medizinische Wochenschrift·2010
    Same journal

    Tuberculous stenoses of the large bronchi.

    Schweizerische medizinische Wochenschrift·2010
    Same journal

    About the enzyme action.

    Schweizerische medizinische Wochenschrift·2010
    See all related articles

    Area of Science:

    • Hepatology
    • Immunology
    • Vaccinology

    Background:

    • Hepatitis B is a frequent infectious disorder in Switzerland.
    • Current vaccines are derived from plasma of healthy carriers, with purification and inactivation processes.
    • Two distinct vaccine formulations will soon be available.

    Purpose of the Study:

    • To introduce the upcoming hepatitis B vaccine in Switzerland.
    • To detail the characteristics and efficacy of the new vaccines.
    • To outline vaccination recommendations for specific populations.

    Main Methods:

    • Description of two new hepatitis B vaccines: Merck Sharp & Dohme and Pasteur Institute formulations.
    • Administration schedules and dosages for each vaccine.
    • Review of preliminary safety and immunogenicity trial data.

    Related Experiment Videos

    Main Results:

    • Vaccines demonstrate safety and induce anti-HBs antibodies in 95-98% of healthy individuals.
    • Over 90% protection against hepatitis B virus (HBV) infection is achieved.
    • Immunosuppressed individuals show a delayed and reduced antibody response but appear protected.

    Conclusions:

    • The new hepatitis B vaccines are safe and highly effective for the general population.
    • Vaccination is recommended for high-risk groups, not mass vaccination.
    • Targeted vaccination strategies will be employed for medical personnel, high-risk patients, and other defined groups.